Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2017

View Archived Issues

FDA confirms regulatory pathway to approval for bempedoic acid/ezetimibe

Phase II trial reveals efficacy of tadekinig alfa in some patients with adult onset Still's disease

Semnur successfully completes phase I/II pharmacokinetic bridging trial of SP-102

Zynerba Pharmaceuticals begins phase I program for ZYN-001

AZD-4785 demonstrates safety and efficacy in preclinical models of KRAS-driven cancer

Ra Pharmaceuticals reports initial data from study of RA-101495 in PNH

Kissei Pharmaceutical identifies NK1 receptor antagonists

Bavarian Nordic reports promising results from phase II study of MVA-BN RSV

Bristol-Myers Squibb presents formylpeptide receptor agonists

SP-1373 has beneficial effects on body and liver weight in obesity models

ST Pharm discloses tankyrase inhibitors

Luc Therapeutics presents NMDA receptor modulators

Chromocell reaches milestone in collaboration with Astellas

Phase I study of KL-1333 begins

Phase II data for voxelotor in pediatric sickle cell disease patients presented

Launch of Inter-Institutional Glial Biology Initiative

Heptares collaborates with New York University on GPCR target implicated in glioblastoma

TrovaGene submits IND for phase Ib/II study of PCM-075

KaloBios Pharmaceuticals' IND for benznidazole in Chagas disease now active

Hanmi's HM-15211 demonstrates benefit in Parkinson's disease and NASH models

Eptinezumab meets primary and key secondary endpoints in phase III PROMISE 1 study

Marinus Pharmaceuticals announces ganaxolone clinical program in postpartum depression

NantCell enters agreement to acquire Altor BioScience

RaNA Therapeutics now Translate Bio

Mepolizumab begins phase III trial in severe bilateral nasal polyps

Sandoz's Erelzi approved in Europe

Eisai withdraws Halaven submission in China with plans to resubmit

Araclon receives Spanish clearance for phase II trials of ABvac40 in early Alzheimer's

Phase III ECHELON-1 trial of Adcetris meets primary endpoint

Maximum tolerated dose determined in phase I study of Wnt pathway inhibitor ETC-159

Sun Pharma and Indian NIV partner on Zika, Chikungunya and dengue

Phase II trial of topical TV-45070 in post-herpetic neuralgia misses endpoints

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...